Zalna 10 mg/0,25 mg v 1 g gel Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zalna 10 mg/0,25 mg v 1 g gel

meda pharma gmbh & co. kg - klindamicin; tretinoin - gel - klindamicin 10 mg / 1 g  tretinoin0,25 mg / 1 g; tretinoin 0,25 mg / 1 g - klindamicin, kombinacije

Zalna 10 mg/0,25 mg v 1 g gel Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zalna 10 mg/0,25 mg v 1 g gel

meda pharma gmbh & co. kg - klindamicin, tretinoin - gel - klindamicin 10 mg / 1 g; tretinoin 0,25 mg / 1 g - klindamicin, kombinacije

Efmody Evropska unija - slovenščina - EMA (European Medicines Agency)

efmody

diurnal europe b.v. - hidrokortizon - adrenal hyperplasia, congenital - kortikosteroidi za sistemsko uporabo - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

LEKADOL COMBO 500 mg/ 12,2 mg prašek za peroralno raztopino Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lekadol combo 500 mg/ 12,2 mg prašek za peroralno raztopino

lek d.d. - fenilefrin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 vrečica  paracetamol500 mg / 1 vrečica; paracetamol 500 mg / 1 vrečica - paracetamol, kombinacije brez psiholeptikov

LEKADOL COMBO 500 mg/ 12,2 mg prašek za peroralno raztopino Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lekadol combo 500 mg/ 12,2 mg prašek za peroralno raztopino

lek d.d. - fenilefrin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 vrečica  paracetamol500 mg / 1 vrečica; paracetamol 500 mg / 1 vrečica - paracetamol, kombinacije brez psiholeptikov

Namuscla Evropska unija - slovenščina - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic motnje - srčna terapija - namuscla je primerna za simptomatsko zdravljenje myotonia pri odraslih bolnikih z ne-dystrophic myotonic motnje.

Rivaroxaban Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

rivaroxaban accord

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotična sredstva - preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 za haemodynamically nestabilno pe bolnikov). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 in 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Cevenfacta Evropska unija - slovenščina - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoragije - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Amlodipin Alkaloid-INT 10 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin alkaloid-int 10 mg tablete

alkaloid - int d.o.o. - amlodipin - tableta - amlodipin 10 mg / 1 tableta - amlodipin

Amlodipin Alkaloid-INT 5 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin alkaloid-int 5 mg tablete

alkaloid - int d.o.o. - amlodipin - tableta - amlodipin 5 mg / 1 tableta - amlodipin